Analysts take a look at Applied Genetic Technologies Corporation (NASDAQ:AGTC) having this to say.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo
Investors sentiment decreased to 1.04 in Q3 2018. Its down 0.89, from 1.93 in 2018Q2. It dived, as 6 investors sold Applied Genetic Technologies Corporation shares while 18 reduced holdings. 8 funds opened positions while 17 raised stakes. 6.33 million shares or 3.28% less from 6.54 million shares in 2018Q2 were reported.
Tower Rech Capital Limited Co (Trc) reported 1,063 shares. Price T Rowe Assocs Md owns 325,444 shares for 0% of their portfolio. Ajo Lp reported 0.01% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Meeder Asset Management holds 0% or 1,408 shares. Vanguard Gp Inc stated it has 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Moreover, Dafna Capital Limited Liability Co has 1.08% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Blackrock Inc owns 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 326,987 shares. Boothbay Fund Management Limited Co owns 58,638 shares for 0.04% of their portfolio. 1,880 were reported by Savings Bank Of Montreal Can. Next Group Inc accumulated 450 shares. Spark Management Llc invested 0.04% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Jacobs Levy Equity Mngmt invested in 0.01% or 77,359 shares. Moreover, Royal State Bank Of Canada has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Northern Tru Corp has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Bridgeway Capital Mngmt has invested 0.01% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC).

Since December 14, 2018, it had 4 buys, and 1 insider sale for $30,744 activity. Shearman Mark S also sold $10,053 worth of Applied Genetic Technologies Corporation (NASDAQ:AGTC) on Friday, December 14. Rosen James also bought $3,381 worth of Applied Genetic Technologies Corporation (NASDAQ:AGTC) shares. $9,990 worth of Applied Genetic Technologies Corporation (NASDAQ:AGTC) was bought by Sullivan William A.. Shares for $19,477 were bought by Aliski William.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Ratings Coverage

Among 3 analysts covering Applied Genetic Tech (NASDAQ:AGTC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Applied Genetic Tech had 3 analyst reports since September 11, 2018 according to SRatingsIntel. Chardan Capital Markets downgraded it to “Neutral” rating and $5 target in Tuesday, September 11 report. The rating was downgraded by BMO Capital Markets on Thursday, December 13 to “Market Perform”. Wells Fargo upgraded Applied Genetic Technologies Corporation (NASDAQ:AGTC) on Monday, September 24 to “Outperform” rating. Below is a list of Applied Genetic Technologies Corporation (NASDAQ:AGTC) latest ratings and price target changes.

13/12/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform New Target: $5 Downgrade
24/09/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Outperform Old Target: $20 New Target: $6 Upgrade
11/09/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Old Target: $10 New Target: $5 Downgrade

The stock decreased 2.19% or $0.07 during the last trading session, reaching $3.13. About 70,834 shares traded. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has risen 60.26% since January 14, 2018 and is uptrending. It has outperformed by 60.26% the S&P500.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $56.76 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.